579results about How to "High titer" patented technology

Provided herein is a retroviral vector comprising, and capable of expressing, a nucleotide of interest (NOI), wherein the NOI encodes an RNA or protein which is harmful to a cell.

The present invention relates to a method for culturing mammalian cells in a culture medium which is transferrin free and which contains no lipophilic or synthetic nitrogen-containing chelators. Also provided is the use of the medium and a process for providing a mammalian product by culturing cells capable of producing the product in the medium.

The invention relates to a preparation method and a product of an H9N2 subtype avian influenza inactivated vaccine. The technical points of the invention mainly relate to the screening, the determination and the domestication of a virus-adapted cell line, the primary amplification cultivation and the continuous cultivation of a virus-adapted cell, the preparation of virus fluid by virus-inoculated culture and the preparation of final inactivated vaccine products. Firstly, the invention avoids the virus propagating method using a large amount of chick embryos in the avian influenza production at present, thereby avoiding the problem of biological potential safety hazards, and overcoming the problem that the mass production of vaccines is enslaved to the supply of the chick embryos; secondly, the invention provides a safe, continuous and closed cell culture virus production method, is used for the preparation of the H9N2 subtype avian influenza inactivated vaccine, enables the use of the cell culture method, and can simultaneously produce high-titer viruses to meet the requirements for the immunological production; and finally, the vaccine production method of the invention is simple and fast, thereby realizing the fast vaccine supply at the epidemic situation.

The present invention relates to a novel polypeptide having anti-tumor activity through inducing apoptosis of endothelial cell and use thereof. More particularly, the present invention relates to a method for inducing apoptosis of endothelial cell, and for preventing or treating cancer, comprising administering to a subject in need thereof an effective amount of (a) an isolated polypeptide having the amino acid sequence of SEQ ID NO: 9 or the amino acid sequence having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 9; or (b) an isolated polynucleotide encoding the polypeptide of (a).

The invention relates to the field of immunomedicine, in particular to an SARS-CoV-2 RBD conjugated nanoparticle vaccine. The vaccine comprises an immunogenic compound, and the immunogenic compound comprises: a) a nanoparticle carrier obtained by self-assembly with a vector protein subjected to fusion expression with SpyCatcher; and b) an RBD antigen of the SARS-CoV-2 virus, which is subjected tofusion expression with SpyTag, the vector protein is selected from Ferritin, mi3 and I53-50, and the vector protein and the antigen are in covalent linkage through SpyCatcher-SpyTag.

The invention relates to an Asia1 type foot-and-mouth disease recombinant virus without pathogenicity for a host and a preparation method and application thereof. A saving system is efficient eukaryotic plasmids which are constructed by gene engineering and can express exact foot-and-mouth disease virus genome RNA (Ribonucleic Acid), and therefore the foot-and-mouth disease recombinant virus can be constructed and prepared; vaccine strains with high titer and good antigen matching property can be prepared by using the plasmids, can be prepared into live vaccines or inactivated vaccines and can effectively stimulate bodies to produce immune response after being used for immunizing pigs and cattle, provide an immune protective effect on the pigs and the cattle and effectively protect GV and GII prevalent strains, the immune protection rate can reach 100 percent, and the median protective dose (PD50) is 6.34 to 13.59; and the recombinant virus has the advantages of high titer, high antigen matching property with the prevalent strains, wide antigen spectrum and high immune protection rate, does not have pathogenicity for pig and cattle hosts, does not form toxemia or expel toxin, and can be applied to prevention and control of Asia1 type foot-and-mouth disease viruses of China and neighboring countries.

The invention relates to a novel coronavirus vaccine and application thereof, in particular to a truncated Spike protein, a fusion protein containing the truncated Spike protein, a nucleic acid molecule containing a nucleotide sequence encoding the truncated Spike protein or the fusion protein, and a vector and a host cell containing the nucleic acid molecule. The invention further relates to a pharmaceutical composition containing the truncated Spike protein, fusion protein, nucleic acid molecule or vector.

The invention relates to a method for improving proliferation capability of mycoplasma gallisepticum in vaccine production, vaccines are prepared through the process steps of preparing seeds, preparing a culture medium of the mycoplasma gallisepticum, preparing vaccine-making bacterial liquid and preparing the inactivated vaccines, after improvement, the content of PPLO (pleuropneumonia-like organism) broth, porcine serum and glucose is increased, MEM (minimum essential medium) ingredients are removed, and the mixture ratio of the ingredients in the culture medium are more scientific and the nutritional value is higher after adjustment. The bacterial liquid concentration of a semi-finished product prepared by the method is as high as 1.0*1013CCU / ml-1.0*1014CCU / ml, and the bacterial liquiddoes not need to be concentrated and can be directly or indirectly used for preparing the inactivated vaccines after dilution, thereby not only simplifying the production process, but also reducing the production cost.

The invention relates to an attenuated vaccine strain of a VII type new castle disease virus with a mutated L gene which is produced by reverse genetic operation technology and a preparation method thereof, and the invention belongs to the fields of biological products and biological technology. The virulence of the attenuated vaccine strain of the VII type new castle disease virus with the mutated L gene is obviously decreased, simultaneously the attenuated vaccine strain has the characteristics of high titer, stable heritability and high matching with the antigen of the epidemic virus according to the chicken embryo experiment; the preparation method is suitable for large scale production of vaccines, and is used for producing vaccines; compared with the conventional vaccines (gene I and gene II types), the attenuated vaccine strain of the VII type new castle disease virus with the mutated L gene has wide application prospects in the aspects of morbidity and epidemic control of new castle disease.

The present invention relates to an adeno-associated virus (AAV) capsid protein mutant, a polynucleotide containing a nucleic acid sequence encoding the AAV capsid protein mutant, a vector containingthe polynucleotide, and a host cell containing the vector. The invention also relates to an adeno-associated vector comprising the AAV capsid protein mutant, a recombinant adeno-associated virion which is constructed from the AAV vector and carries a gene expression cassette, a method for producing the adeno-associated virus vector or virion, and an application of the adeno-associated virus vectorand virion in treating diseases.

The invention discloses a preparation method of a complex live vaccine for porcine reproductive and respiratory syndrome, belonging to the technical field of veterinary biological products. The preparation method comprises the following steps: (1) culturing master cells; (2) performing suspension culture on vaccine preparation cells; (3) culturing and harvesting viruses; (4) performing mixed adsorption on the harvested full-suspension virus solution and chicken anti-porcine reproductive and respiratory syndrome virus egg yolk antibody; (5) adding the adsorbed antigen-antibody compound into an immunoenhancer-containing freeze-drying protecting agent, sub-packaging and then performing freeze vacuum drying to prepare the complex live vaccine for the porcine reproductive and respiratory syndrome. The method is used for preparing the vaccine, and has the characteristics that the production period can be shortened, the personnel allocation is reduced, the pollution probability is low, the floor area is small, the virus titer is high, the difference between the prepared vaccine batches is small, the product has stable and high-efficiency quality, the side effect is small and the quality of the vaccine can be completely improved.